Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Study Designs in Epidemiology01:20

Study Designs in Epidemiology

182
Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
182
Introduction to Epidemiology01:26

Introduction to Epidemiology

650
Epidemiology, known as the cornerstone of public health, involves studying the distribution and determinants of health-related events in defined populations and applying these insights to control health issues. This is essential for understanding how diseases spread, identifying populations at greater risk, and implementing measures to control or prevent outbreaks. Epidemiology addresses not only infectious diseases but also non-communicable conditions like cancer and cardiovascular disease,...
650
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

595
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
595
Pharmacovigilance01:19

Pharmacovigilance

773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Infections and severe mental illness: a population-based matched cohort study.

BMJ mental health·2026
Same author

Reply to: Re-Examining Sedative and Hypnotic Prescribing Following Hip Fracture.

Journal of the American Geriatrics Society·2026
Same author

Extending inferences from a randomized trial to trial-eligible and treatment-candidate target populations: examples of generalizability and transportability.

Epidemiology (Cambridge, Mass.)·2026
Same author

Transporting: What Is It and How Do You Do It?

Current epidemiology reports·2026
Same author

Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating Agents.

Kidney medicine·2026
Same author

The heterogeneous treatment effects of statins on dementia: a target trial emulation with causal machine learning using integrated genetic and real-world data.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jun 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Core Concepts in Pharmacoepidemiology: New-User Designs.

Qoua L Her1, Julie Rouette2, Jessica C Young3

  • 1Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Pharmacoepidemiology and Drug Safety
|November 25, 2024
PubMed
Summary

Pharmacoepidemiology uses new-user study designs to compare drug safety and effectiveness. This review details three designs: new-user vs. non-user, active comparator new-user (ACNU), and prevalent new-user (PNU) for robust clinical trial emulation.

Keywords:
active comparator new user designnew‐user designpharmacoepidemiologyprevalent new user design

More Related Videos

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.5K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K

Related Experiment Videos

Last Updated: Jun 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study
20:24

Characterization of Complex Systems Using the Design of Experiments Approach: Transient Protein Expression in Tobacco as a Case Study

Published on: January 31, 2014

16.5K
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

9.6K

Area of Science:

  • Pharmacoepidemiology
  • Drug safety and effectiveness research
  • Clinical trial design emulation

Background:

  • New-user comparisons are crucial in pharmacoepidemiology for understanding real-world drug effects.
  • Existing methods often lack a unifying framework, leading to inconsistencies in study design and interpretation.
  • The target trial framework offers a standardized approach to emulate randomized controlled trials using observational data.

Purpose of the Study:

  • To review the historical context and rationale behind new-user comparisons in pharmacoepidemiology.
  • To introduce and describe three distinct new-user study designs: new-user vs. non-user, active comparator new-user (ACNU), and prevalent new-user (PNU).
  • To discuss how these designs address critical issues like defining 'time zero', selecting appropriate comparators, and managing sources of bias.

Main Methods:

  • Review of historical literature and key concepts in pharmacoepidemiological study design.
  • Description and categorization of three primary new-user study designs.
  • Application of a clinical example (hormone replacement therapy and coronary heart disease risk) to illustrate practical considerations.

Main Results:

  • The target trial framework provides a unifying structure for new-user study designs.
  • Each design (new-user vs. non-user, ACNU, PNU) has specific strengths and limitations regarding bias control and applicability.
  • Defining 'time zero' and selecting appropriate comparator groups are critical for valid study execution.

Conclusions:

  • The three presented new-user study designs offer distinct approaches to emulating target trials in pharmacoepidemiology.
  • Careful consideration of time zero definition, comparator selection, and potential biases is essential for each design.
  • These designs facilitate more rigorous and interpretable pharmacoepidemiological research, enhancing drug safety and effectiveness evaluations.